Skip to main content

DCVC Bio — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

56
Companies
$2.6B
Total invested
$64.0M
Avg. check
28
Industries
Biotechnology 18Medical 9Therapeutics 8Biopharma 5Health Care 5Manufacturing 5+22 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 56
GenEdit
January 2024

GenEdit develops next generation therapeutics for genetic diseases through safe and efficient CRISPR/Cas9 delivery.

Biotechnology · South San Francisco$24.0M Series A
Totus Medicines
December 2023

Totus Medicines employs uses AI/ML and innovative DNA-encoded covalent library tech to discover small molecule medicines.

Biopharma · Cambridge$66.0M Series B
Radionetics Oncology
August 2023

Radionetics Oncology is a pharmaceutical company that focuses on the discovery and development of novel radiotherapeutics.

Health Care · California City$52.5M Series A
Orca Bio
January 2026

Orca Bio is a clinical-stage cell therapy company dedicated to delivering curative medicine to patients.

Health Care · Menlo Park$250.0M Series F
CH4 Global
January 2025

CH4 Global mission is to use sustainable aquaculture to impact climate change at scale.

Agriculture · HendersonCorporate Round
Umoja Biopharma
January 2025

Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer.

Biopharma · Seattle$100.0M Series C
NILO Therapeutics
October 2025

NILO Therapeutics is a biotechnology and therapeutics company.

Biotechnology · New York$101.0M Series A
AgZen
March 2026

AgZen develops pesticide sprays stick to plants which reduces pollution and helps farmers save.

Agriculture · Somerville$10.0M Series B
SyntaxBio
December 2025

SyntaxBio develops genetic programming platform that can program cells without the need for consistent external intervention.

Biotechnology · Chicago$856K Grant
Latus Bio
August 2025

Latus Bio focuses on developing innovative gene therapy candidates using precision delivery to enhance the lives of patients.

Biopharma · PhiladelphiaSeries A
Estes Energy
July 2025

Estes Energy is a California-based startup developing advanced, U.S.-made, chemistry-agnostic battery packs for mobility and industry.

Chemical · San Francisco$11.0M Seed
Auron Therapeutics
July 2025

Auron aims to cure cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells.

Biotechnology · NewtonSeries Unknown
Grove Biopharma
April 2025

Grove Biopharma is a biotechnology company offering a materials science solution to peptide therapeutic challenges.

Analytics · Chicago$30.0M Series A
Solu Therapeutics
April 2025

Solu Therapeutics Platform Company that develops antibody-based medicines using a degradable warhead.

Biotechnology · Boston$41.0M Series A
Newleos Therapeutics
February 2025

Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.

Biotechnology · Boston$93.5M Series A
MycoWorks
July 2024

MycoWorks is a biotechnology company that offers non-plastic and non-animal materials to the market.

Biotechnology · EmeryvilleSeries D
Frontier Medicines
June 2024

Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines.

Biopharma · San Francisco$20.0M Series C
Valar Labs
May 2024

Valar Labs offers assistance services for cancer treatment through Artificial Intelligence.

Artificial Intelligence (AI) · Palo Alto$22.0M Series A
Ascend Gene & Cell Therapies
May 2023

Ascend Gene & Cell Therapies is a model for gene and cell therapy manufacturing.

Biotechnology · Potters Bar$65.9M Series A
Empirico
March 2023

Empirico is a developer of an insights platform designed to turn biological insights from human genetics into new medicines.

Biotechnology · San Diego$45.2M Series B
Novome Biotechnologies
September 2022

Novome Biotechnologies is a biotechnology company focused on engineering defined activities into the human.

Biopharma · South San Francisco$43.5M Series B
Verdant Robotics, Inc.
August 2022

Verdant builds AI-powered Smart Sprayers that weed, thin, fertilize & deliver nutrients at millimeter level.

Agriculture · Hayward$46.5M Series A
Creyon Bio
March 2022

Reinventing drug development from the ground up to make safe, effective oligonucleotide-based medicines possible on demand.

Biotechnology · San Diego$40.0M Series A
Stemson Therapeutics
July 2021

Stemson Therapeutics is a pre-clinical stage cell therapy company.

Biotechnology · San Diego$15.0M Series A

Where DCVC Bio invests

Biotechnology18
Medical9
Therapeutics8
Biopharma5
Health Care5
Manufacturing5

About DCVC Bio's portfolio

How many companies has DCVC Bio invested in?

DCVC Bio has invested in 56 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does DCVC Bio invest in?

DCVC Bio's top investment sectors include Biotechnology, Medical, Therapeutics, Biopharma, Health Care. The firm invests across 28 different industry categories.

What is DCVC Bio's largest investment?

Among tracked funding rounds, Orca Bio received $250.0M in a Series F round. DCVC Bio's total known invested capital is $2.6B.

What is the average investment size for DCVC Bio?

DCVC Bio's average investment size is $64.0M across its portfolio of 56 companies.

What are DCVC Bio's most recent investments?

Recent DCVC Bio portfolio additions include GenEdit, Totus Medicines, Radionetics Oncology, Orca Bio, CH4 Global. These companies were founded in 2020 or later.

Reach the founders behind these 56 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →